Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Other financing activities (2018 - 2025)

Dexcom (DXCM) has disclosed Other financing activities for 8 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities fell 18.75% to -$1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.0 million, a 46.15% increase, with the full-year FY2025 number at -$7.0 million, up 46.15% from a year prior.
  • Other financing activities was -$1.9 million for Q4 2025 at Dexcom, down from -$1.7 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $4.9 million in Q4 2023 to a low of -$8.7 million in Q1 2024.
  • A 5-year average of -$2.3 million and a median of -$1.5 million in 2024 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: tumbled 3850.0% in 2021, then skyrocketed 590.0% in 2023.
  • Dexcom's Other financing activities stood at -$800000.0 in 2021, then dropped by 25.0% to -$1.0 million in 2022, then surged by 590.0% to $4.9 million in 2023, then crashed by 132.65% to -$1.6 million in 2024, then fell by 18.75% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Other financing activities are -$1.9 million (Q4 2025), -$1.7 million (Q3 2025), and -$1.7 million (Q2 2025).